Cleared Traditional

K103687 - SYNAPSE 3D CEREBRAL ANALYSIS

K103687 is the FDA 510(k) clearance for SYNAPSE 3D CEREBRAL ANALYSIS by Fujifilm Medical System U.S.A., Inc.. It is a Class 2 Radiology device (product code LLZ) cleared through the Traditional 510(k) pathway after a 77-day FDA review.

K103687 · Fujifilm Medical System U.S.A., Inc. · Radiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2011
Decision
77d
Days
Class 2
Risk

K103687 is an FDA 510(k) clearance for the SYNAPSE 3D CEREBRAL ANALYSIS. Classified as System, Image Processing, Radiological within the LLZ classification (a category encompassing advanced image processing and PACS-adjacent software), Class II - Special Controls.

Submitted by Fujifilm Medical System U.S.A., Inc. (Stamford, US). The FDA issued a Cleared decision on March 4, 2011 after a review of 77 days - a notably fast clearance cycle.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2050 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Incremental AI imaging tool. Moderate equivalence dependency. Overall, this clearance reflects a predicate-aligned approval typical of modern AI radiology extensions - not a novel clinical breakthrough, but a validated iteration within an established regulatory category.

View all Fujifilm Medical System U.S.A., Inc. devices

Submission Details

510(k) Number K103687 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 17, 2010
Decision Date March 04, 2011
Days to Decision 77 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
30d faster than avg
Panel avg: 107d · This submission: 77d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LLZ System, Image Processing, Radiological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.2050
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Radiology devices follow this clearance model.

Regulatory Peers - LLZ System, Image Processing, Radiological

All 1127
Devices cleared under the same product code (LLZ) and FDA review panel - the closest regulatory comparables to K103687.
SYNAPSE 3D LUNG AND ABDOMEN ANALYSIS
K103720 · Fujifilm Medical Systems U.S.A, Inc. · Mar 2011
THORACIC VCAR
K103480 · Ge Medical Systems, LLC · Mar 2011
VIEWPOINT 6
K103458 · Ge Healthcare · Mar 2011
BARCO MAMMO TOMOSYNTHESIS
K103792 · Barco N.V. · Mar 2011
SECURVIEW DX DIAGNOSTIC WORKSTATION
K103385 · Hologic, Inc. · Feb 2011
SYNAPSE 3D CARDIAC TOOLS
K103465 · Fujifilm Medical Systems U.S.A, Inc. · Jan 2011